Boston Scientific warrants caution because its debt levels leave it behind much cleaner, higher-quality medical-device stories. x.com 

Boston Scientific's key franchises look vulnerable to competition in 2027, with a big acquisition at a bad multiple seeming the solution. Insider buying is the only positive; it makes a random bounce to $60 very likely, but the stock is still unconvincing. The possible bull case is that management knows the acquisition will go very well and is buying the dip. x.com 

Boston Scientific looks reasonably priced for the risk after a 45% drawdown. It is a cardiology medtech leader with high-single-digit organic growth, a strong margin profile and a proven eye for tuck-in M&A, now at a mid-to-high-teens P/E, a discount to the market where it historically traded at a premium. The selloff happened for a reason, and the case fails only if the Penumbra deal and current revenue scale mean its growth is over. x.com  x.com 

Nike does not merit a high-teens earnings multiple. Wingstop, CRH and Boston Scientific are much better fallen names right now: after big de-ratings they still trade cheaper than Nike while offering real growth and less long-term risk. x.com 

Better underwriting at Root, AI data demand at Innodata, defense breadth at Applied Aerospace & Defense, scaled voice AI at SoundHound, more organ access via TransMedics, profitable insurance at Lemonade, autonomous defense at Ondas and successful medicines at AbCellera could drive outsized growth. These eight smaller companies have a realistic path to 5x+ over 5-10 years if they execute on those opportunities. x.com  x.com  x.com  x.com  x.com  x.com  x.com  x.com 

Boston Scientific seems to have a lot priced in: shares are flat over five years while the business has doubled. Revenue roughly doubled, mainly from Farapulse and Watchman rather than M&A; operating income rose from $1.8B to $4.1B, EPS grew 3.5x to $2.40, margins expanded and free cash flow more than doubled with flat share count. Growth is slowing from high levels amid new competition and possible GLP-1 effects on case volumes, but medtech offers a margin of safety until the market rotates. … Show more

Boston Scientific has slipped back into a downtrend since recalling its Imager II Angiographic Catheters over a manufacturing issue with the catheter tip that caused two patient injuries. It stopped selling the product and lowered guidance as a result, and it is unclear what would reverse the trend. x.com 

Intuitive Surgical sits at multi-year-low forward valuations, at times below its 2022 trough and late-2010s lows over the last six quarters, though cheap can get cheaper, as it did after earnings. The concern with higher-cost exposure is China, not competition from J&J's Ottava or Medtronic's Hugo. The stock is tricky to read through sector correlation because it straddles medical devices, the Nasdaq 100 and momentum. x.com 

Boston Scientific looks cheap on an estimate-based cash-earnings screen: 13x current and 12x next year's cash earnings versus 14x for medical-device makers imply a $43.85-$55.81 fair range against $42.04. This is a levels-only comparison using reported estimates, not fundamental diligence. x.com 

De facto monopolies compound only when they have a reinvestment runway, not just a moat. TSMC ploughs profits into the next node, Intuitive Surgical into new procedures and installed base, and CoStar into new data verticals and regions, redeploying cash at high rates. A monopoly with no runway, like a toll road or regulated utility, is effectively a bond whose moat tempts investors to overpay. The screen tests genuine monopoly share, reinvestment runway and ROIC against its five-year average. … Show more